Sac-TMT Combo Shows Promise in Metastatic Prostate Cancer Treatment
Summary of Sac-TMT Plus Pembrolizumab in Metastatic CRPC
This text details the results of a phase 2 study evaluating the combination of sac-TMT (a T-cell engager) and pembrolizumab (an immune checkpoint inhibitor) in patients with previously treated metastatic castration-resistant prostate cancer (CRPC). Here’s a breakdown of the key findings:
Key Results (Cohort D - Prostate Cancer):
* PSA50 Response: 39% of all evaluable patients (n=46) experienced a ≥50% reduction in prostate-specific antigen (PSA).
* Objective Response Rate (ORR): 47% (95% CI, 24%-71%) in patients with measurable disease (n=19). This included:
* Complete Responses (CR): 5%
* Partial responses (PR): 42%
* Disease Control Rate (DCR): 90% (95% CI, 67%-99%)
* Dose-dependent Activity:
* 4 mg/kg Sac-TMT (n=10): PSA50 response 50%, ORR 75%, DCR 100% (all PRs)
* 5 mg/kg Sac-TMT (n=36): PSA50 response 36%, ORR 40%, DCR 87% (7% CR, 33% PR)
* Safety: The combination was considered manageable, with a safety profile consistent with the individual drugs. No new safety signals were observed.
Study Details:
* Study Design: Phase 2 trial evaluating sac-TMT plus pembrolizumab in multiple solid tumor types (cohorts A-E).
* patient Population (Cohort D): Patients with metastatic CRPC who had progressed on hormonal therapy and received ≤1 prior chemotherapy regimen.
* Treatment: Sac-TMT (4 mg/kg or 5 mg/kg) every 2 weeks + Pembrolizumab (400 mg) every 6 weeks.
* Endpoints: Safety, ORR, and PSA50 response rate.
Conclusion:
the study authors concluded that the combination of sac-TMT and pembrolizumab demonstrated encouraging antitumor activity and a manageable safety profile in patients with previously treated metastatic CRPC, supporting further advancement of this combination.
Reference:
- Presented at the European society for Medical Oncology (ESMO) Congress 2025.
- The study included patients with cervical, urothelial, ovarian, prostate, and endometrial cancers.